Characterization of serum anti-diphtheria antibody activity following administration of equine anti-toxin for suspected diphtheria
Department of Pediatrics, Division of Pediatric Immunology and Infectious Diseases; MassBiologics
Immunoprophylaxis and Therapy
There is a global shortage of equine-derived diphtheria anti-toxin (DAT) for diphtheria treatment. There are few existing data on serum antibody concentrations and neutralizing activity post-treatment to support development of new therapeutics. Antibody concentrations were quantified by ELISA and anti-toxin neutralizing activity by cytotoxicity assay in serum from 4 patients receiving DAT for suspected diphtheria. Using linear mixed effects modeling, estimated mean (SE) half-life was 78.2 (20.0) hours. Maximum serum neutralizing activity ranged from 28.42-38.64 AU/mL with an estimated mean AUC1-72 of 1396.7 (399.3) AU/mL*hr. These data provide a standard of comparison for development of novel anti-toxins to replace DAT.
DOI of Published Version
Hum Vaccin Immunother. 2017 Sep 21:1-4. doi: 10.1080/21645515.2017.1362516. Link to article on publisher's site
Human vaccines and immunotherapeutics
Smith HL, Saia G, Lobikin M, Tiwari T, Cheng S, Molrine DC. (2017). Characterization of serum anti-diphtheria antibody activity following administration of equine anti-toxin for suspected diphtheria. Pediatric Publications. https://doi.org/10.1080/21645515.2017.1362516. Retrieved from https://escholarship.umassmed.edu/peds_pp/177